Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Operations (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash from Operations for 11 consecutive years, with 69285000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 18.67% to 69285000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 394736000.0, a 13.14% decrease, with the full-year FY2025 number at 394736000.0, down 13.14% from a year prior.
  • Cash from Operations was 69285000.0 for Q4 2025 at Intellia Therapeutics, up from 76899000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 52376000.0 in Q1 2021 to a low of 148930000.0 in Q1 2025.
  • A 5-year average of 84800950.0 and a median of 84964000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 192.27% in 2021, then soared 35.58% in 2024.
  • Intellia Therapeutics' Cash from Operations stood at 54651000.0 in 2021, then tumbled by 64.44% to 89869000.0 in 2022, then dropped by 3.54% to 93054000.0 in 2023, then rose by 8.45% to 85195000.0 in 2024, then increased by 18.67% to 69285000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Cash from Operations are 69285000.0 (Q4 2025), 76899000.0 (Q3 2025), and 99622000.0 (Q2 2025).